Nursing Pharmacology Practice Questions: Chapter 33-34 Humanized monoclonal antibody Binding to HER2 Protein : trastuzumab (Herceptin)

Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Humanized monoclonal antibody that binds to HER2 Protein : Trastuzumab (Herceptin)

Trastuzumab (Herceptin):
1. IgG1 Monoclonal antibody
2. Binds to extracellular domain IV of HER2.
3. Both
4. Neither
HER2:
1. From: Human Epidermal Growth Factor Receptor 2
2. Receptor tyrosine-protein kinase ERBB2
3. Both
4. Neither
HER2: Similar structure to human epidermal growth factor receptor (HER1)
1. True
2. False
Consequence(s) of transtuzumab binding to HER2:
1. Inhibits protein homo-and heterodimerization as well as signal transduction
2. Transtuzumab binding to HER2 overexpressing cells induce immune cell-mediated cytotoxicity.
3. Both
4. Neither
Response/responses associated with increased likelihood of positive clinical response to HER2-targeted treatments.
1. HER2 gene amplification
2. HER2 protein overexpression
3. Both
4. Neither
Trastuzumab, a humanized monoclonal antibody (IgG1_kappa) can be used as monotherapy in:
1. Metastatic breast cancer whose tumors do not express HER2 protein.
2. Metastatic breast cancer in combination treatment with paclitaxel for patients whose tumors both overexpress HER2 protein and if previously not received chemotherapeutic intervention.
3. Both
4. Neither
Trastuzumab:
1. May be used in combination with taxanes as initial treatment.
2. May be used as a single agent following treatment failure after cytotoxic chemotherapy.
3. Both
4. Either
Trastuzumab is been approved for:
1. Gastric cancer
2. HER2-overexpressing breast cancer
3. Both
4. Neither
Transtuzumab pharmacokinetics: Transtuzumab concentrations will decrease by about 97% seven months following cessation of treatment.
1. True
2. False
Trastuzumab exposure during pregnancy may result in pulmonary hypoplasia, skeletal malformations, and neonatal death.
1. True
2. Falls